Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04744935 · ClinicalTrials.gov registry record · NA

Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma

A NA study of Basal Cell Carcinoma and Superficial Basal Cell Carcinoma, sponsored by Christopher Zachary.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT04744935 is a NA study of Basal Cell Carcinoma and Superficial Basal Cell Carcinoma that is actively recruiting participants, run by Christopher Zachary. The registered enrollment target is 40 participants, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04744935, a NA study of Basal Cell Carcinoma and Superficial Basal Cell Carcinoma, is actively recruiting participants, sponsored by Christopher Zachary.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Optical coherence tomography guided laser treatment of basal cell carcinoma

Interventions

  • DEVICE 1064 nm long-pulse Nd:YAG laser

Study Locations (1)

California

  • UCI Health Gottschalk Medical Plaza - Irvine

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-01-13
Est. Completion 2025-12-31
Phase NA

Sponsor

Christopher Zachary

1 total trials

What the Registry Record Tells You About NCT04744935

The ClinicalTrials.gov registry entry for NCT04744935 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Christopher Zachary, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which 1064 nm long-pulse Nd:YAG laser is the first listed.

NCT04744935 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04744935 about?

NCT04744935 is a clinical study titled "Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma". Optical coherence tomography guided laser treatment of basal cell carcinoma

What is the current status of trial NCT04744935?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2021-01-13. Estimated completion is 2025-12-31.

What conditions does trial NCT04744935 study?

This clinical trial studies the following conditions: Basal Cell Carcinoma, Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma.

What interventions are being tested in trial NCT04744935?

The interventions under investigation include: 1064 nm long-pulse Nd:YAG laser (DEVICE).

Who is sponsoring clinical trial NCT04744935?

This trial is sponsored by Christopher Zachary, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04744935 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Basal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.